Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients

Therapeutic Drug Monitoring

Volumn 27, Issue 4, 2005, Pages 491-498

  Solassol, Isabelle ^c   Bressolle, Françoise ^a   Caumette, Laetitia ^c   Garcia, Frédéric ^c   Poujol, Sylvain ^c   Culine, Stéphane ^b   Pinguet, Frédéric ^c  

^a UNIV MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

^c Faculté de Pharmacie ^*

Author keywords

Cancer pain patients; Fentanyl; Pharmacokinetics; Transdermal applications

Indexed keywords

COCODAMOL; FENTANYL; MORPHINE; MORPHINE SULFATE;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PAIN; CLINICAL ARTICLE; DEVICE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NOCICEPTION; PAIN ASSESSMENT; PRIORITY JOURNAL; VISUAL ANALOG SCALE;

ACETAMINOPHEN; ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC DISEASE; CODEINE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; PAIN MEASUREMENT; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 23244441284     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000160717.50704.42     Document Type: Article

References (29)

1. Villiger JW, Ray LJ, Taylor KM. Characteristics of [3H]fentanyl binding to the opiate receptor. Neuropharmacology. 1983;22:447-452.
2. Tawfik MO, Bryuzgin V, Kourteva G. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin. 2004;20:259-267.
3. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001;61:2289-2307.
4. Gupta SK, Southam M, Gale R, et al. System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Manage. 1992;7(Suppl 3):S17-S26.
5. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med. 1996; 335:1124-1132.
6. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353: 1695-1700.
7. Rose PG, Macfce MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg. 1993;77:390-391.
8. Ashburn MA, Ogden LL, Zhang J, et al. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain. 2003; 4:291-297.
9. Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989;70:928-934.
10. Broome U, Wright BM, Bower S, et al. Postoperative analgesia with transdermal fentanyl following lower abdominal surgery. Anaesthesia. 1995;50:300-303.
11. Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology. 1993;78: 36-43.
12. Esteve M, Levron JC, Flaisler B, et al. Does aging modify pharmacokinetics of transdermal fentanyl. Anesthesiology. 1991;75(Suppl): A705.
13. Plezia PM, Kramer TH, Linford J, et al. Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy. 1989; 9:2-9.
14. Van Bastelaere M, Roily G, Van Peer A, et al. Pharmacokinetic behaviour of transdermal fentanyl. Br J Anaesth. 1993;70(Suppl 1):75.
15. Hanna MH and Wodding S. A study to examine the repeat dose pharmacokinetics of TTS (fentanyl) using repeated 72-hour applications for a 6 day period in patients with cancer pain or intractable pain requiring opioid therapy. Janssen Research Fondation, data of file, Trial number FEN-GBR-008.
16. Durcan TG, Sockalingham MH, Hanna M, et al. Pharmacokinetics study of repeated 72 hour applications of TTS-fentanyl. Br J Anaesth. 1995;74 Suppl. 1:139.
17. Gourlay GK, Kowalski SR, Plummer JL, et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain. 1990;40:21-28.
18. Gourlay GK, Kowalski SR, Plummer JL, et al. The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. Pain. 1989;37: 193-202.
19. Bell SD, Goldburg ME. Comparison of single patch multi-day versus multiple patch single day TTS fentanyl. Can J Anaesth. 1989;36:116-117.
20. Southam MA. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. Anticancer Drugs. 1995;6(Suppl 3):29-34.
21. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53:109-138.
22. Gourlay GK. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol. 2001;2:165-172.
23. Ariano RE, Duke PC, Sitar DS. Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol. 2001;41:757-763.
24. Kumar K, Ballantyne JA, Baker AB. A sensitive assay for the simultaneous measurement of alfentanil and fentanyl in plasma. J Pharm Biomed Anal. 1996;14:667-673.
25. Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother. 1995;29:969-911.
26. Shou WZ, Pelzer M, Addison T, et al. An automatic 96-well solid phase extraction and liquid chromatography-tandem mass spectrometry method for the analysis of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human plasma. J Pharm Biomed Anal. 2002;27:143-152.
27. Pk-fit computer program. Version 2.1. Montpellier. France: RDPP, 1999.
28. Farenc C, Fabreguette JR, Brcssolle F. Pk fit: a pharmacokinetic/ pharmacodynamic and statistical data analysis software. Comput Biomed Res. 2000;33:315.
29. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos. 1996;24:932-939.